ELTX Files 8-K Announcing Peer-Reviewed Publication of AMPLIFY-201 Follow-Up

Rhea-AI Filing Summary

Elicio Therapeutics reported that follow-up data from its Phase 1 AMPLIFY-201 study of ELI-002 were published in the peer-reviewed journal Nature Medicine. The company issued a press release announcing the publication, which is attached to this report as Exhibit 99.1 and incorporated by reference. The filing identifies the company as a Delaware corporation with common stock trading under the ticker ELTX on The Nasdaq Capital Market. This disclosure is limited to the publication notice and the inclusion of the press release as an exhibit; no financial results, trial outcomes, or operational actions are presented within the report.

Positive

• Peer-reviewed publication: Follow-up data from the Phase 1 AMPLIFY-201 study of ELI-002 were published in Nature Medicine
• Formal disclosure: The company issued a press release announcing the publication and filed it as Exhibit 99.1, providing investors an official source

Negative

• None.

Insights

Biotechnology Analyst

TL;DR: Publication in a top-tier peer-reviewed journal signals scientific validation but the filing itself contains no clinical outcome details.

The filing confirms that follow-up data from the Phase 1 AMPLIFY-201 study of ELI-002 were published in Nature Medicine and that a press release is attached as Exhibit 99.1. From a scientific perspective, peer-reviewed publication tends to increase visibility and credibility among researchers and potential collaborators. However, because the 8-K only announces the publication and does not disclose the data, safety signals, endpoints, or statistical results, investors cannot assess efficacy, regulatory prospects, or commercial impact from this filing alone.

Securities Analyst

TL;DR: The disclosure is procedural and informative; it is notable but not, by itself, materially transformative for financial valuation.

The report documents a corporate communication about the peer-reviewed publication and includes the press release as an exhibit. For market impact, filings that merely announce publication without presenting new quantitative clinical outcomes, guidance, partnerships, or financial metrics typically produce limited immediate pricing reaction. The exhibit attachment does centralize investor access to the press release, but absent additional material facts in this 8-K, there is insufficient information here to reassess revenue prospects, timelines, or capital needs.

0001601485false08/12/2025Nasdaq00016014852024-06-302024-06-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 12, 2025

Elicio Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-39990			11-3430072
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(IRS Employer Identification No.)
			451 D Street, 5th Floor
			Boston, Massachusetts 02210
			(Address of principal executive offices, including zip code)

(857) 209-0050

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

(Title of each class)			(Trading Symbol)			(Name of exchange on which registered)
Common Stock, $0.01 par value per share			ELTX			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01 Other Events.

On August 12, 2025, Elicio Therapeutics, Inc. (the “Company”) issued a press release announcing the publication of follow-up data from the Company’s Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed scientific journal, Nature Medicine. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number						Exhibit Description
99.1						Press Release dated August 12, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Elicio Therapeutics, Inc.

By:

/s/ ROBERT CONNELLY

Date: August 12, 2025

Robert Connelly President and Chief Executive Officer (Principal Executive Officer)

FAQ

What did Elicio Therapeutics (ELTX) disclose in this 8-K?

The company announced the publication of follow-up data from its Phase 1 AMPLIFY-201 study of ELI-002 in the peer-reviewed journal Nature Medicine and filed a press release as Exhibit 99.1.

Does the 8-K include the clinical data or trial results for ELI-002?

No. The 8-K states that follow-up data were published and that a press release is attached; it does not disclose the underlying clinical data or specific trial outcomes.

Where can investors find the press release mentioned in the filing?

The press release announcing the publication is attached to the report as Exhibit 99.1 and is incorporated by reference in the filing.

What securities information is provided for Elicio in the filing?

The filing states the company’s common stock trades under the ticker ELTX on The Nasdaq Capital Market.

Does the 8-K disclose any financial statements or operational actions?

No. The report is limited to the publication announcement and the press release exhibit; it does not include financial statements, earnings data, or operational transactions.